U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07712042) titled 'Tafolecimab in Hyperlipidemia: A Study of Different Dosing Intervals' on July 10.
Brief Summary: This is a prospective, observational cohort study. Patients will be assigned to either the Q2W or Q3W group based on the treating physician's clinical decision, not by randomization. The aim is to evaluate the real-world effectiveness and safety of the two dosing regimens.This study aims to systematically evaluate the lipid-lowering efficacy and safety of two dosing regimens of Tafolecimab 150 mg-administered every two weeks (Q2W) versus every three weeks (Q3W)-over a 12-week period in patients with hyperlipidemia whose LDL-C remains abo...